Citigroup reiterates Sepracor at buy/high risk

Sepracor Inc. was reiterated by Citigroup Investment Research analyst Andrew Swanson at a buy/high risk rating after competitor Neurocrine Biosciences announced the FDA is delaying the action date for its insomnia drug. That gives Sepracor time to cement Lunesta's marketing message with physicians before Neurocrine and Pfizer begin the marketing push for their insomnia drugs. Shares of the Marlborough, Mass., pharmaceutical company were up 97 cents, or 1.87%, at $52.75 on volume of 2,664,853 shares versus the three-month running average of 1,728,020 shares. (Nasdaq: SEPR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.